Pediatric Cancer - Pipeline Review, Q2 2011Global Markets DirectApril 30, 2011 59 Pages - SKU: GMD6354562 |
- Introduction
- Introduction
- Global Markets Direct Report Coverage
- Pediatric Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Pediatric Cancer
- Pediatric Cancer Therapeutics under Development by Companies
- Pediatric Cancer Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Pediatric Cancer Therapeutics - Products under Development by Companies
- Pediatric Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Pediatric Cancer Therapeutics Development
- Astex Therapeutics Limited
- Geron Corporation
- Hana Biosciences, Inc.
- Pediatric Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- GRN163L - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AT9283 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Marqibo - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Zactima + Isotretinoin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ispinesib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Filgrastim + Carboplatin + Cyclophosphamide + Etoposide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Filgrastim + Carboplatin + Cyclophosphamide + Etoposide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Flavopiridol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Flavopiridol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bevacizumab + Lapatinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Etoposide + Autologous bone marrow reinfusion - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Interferon alfa + Cisplatin + Fluorouracil + Radiation therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- COPP + ABV - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Therapeutic autologous dendritic cells + indinavir sulfate + stem cell transplantation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Anti-Thymocyte Globulin + Busulfan + Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Isotretinoin + Vorinostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Isotretinoin + Vorinostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SCH 717454 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MLN8237 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SVV-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pediatric Cancer Therapeutics - Drug Profile Updates
- Pediatric Cancer - Featured News
- Feb 24, 2010: Enzon Opens Pediatric Study Of PEG-SN38
- Jun 19, 2007: OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Pediatric Cancer, Q2 2011
- Products under Development for Pediatric Cancer - Comparative Analysis, Q2 2011
- Number of Products under Development by Companies, Q2 2011
- Number of Products under Investigation by Universities/Institutes, Q2 2011
- Comparative Analysis by Mid Clinical Stage Development, Q2 2011
- Comparative Analysis by Early Clinical Stage Development, Q2 2011
- Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
- Products under Development by Companies, Q2 2011
- Products under Investigation by Universities/Institutes, Q2 2011
- Astex Therapeutics Limited, 2011
- Geron Corporation, 2011
- Hana Biosciences, Inc., 2011
- Assessment by Monotherapy Products, Q2 2011
- Assessment by Combination Products
- Assessment by Stage and Route of Administration, Q2 2011
- Assessment by Molecule Type, Q2 2011
- Pediatric Cancer Therapeutics - Drug Profile Updates
- List of Figures
- Number of Products under Development for Pediatric Cancer, Q2 2011
- Products under Development for Pediatric Cancer - Comparative Analysis, Q2 2011
- Products under Development by Companies, Q2 2011
- Products under Investigation by Universities/Institutes, Q2 2011
- Mid Clinical Stage Products, Q2 2011
- Early Clinical Stage Products, Q2 2011
- Pre-Clinical Stage Products, Q2 2011
- Assessment by Monotherapy Products, Q2 2011
- Assessment by Combination Products, Q2 2011
- Assessment by Route of Administration, Q2 2011
- Assessment by Stage and Route of Administration, Q2 2011
- Assessment by Molecule Type, Q2 2011
- Assessment by Stage and Molecule Type, Q2 2011
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Oncology/Hematology Reports